SL Science presents glioblastoma treatment data at WCP 2026

SL Science presents glioblastoma treatment data at WCP 2026

U.S. futures slide with AI worries in focus; Netflix disappoints TAIPEI, TAIWAN - SL Science Holding Limited (NASDAQ:SLBT) announced its participation at the 2026 World Congress of Basic and Clinical Pharmacology held July 12-17 in Melbourne, Australia, according to a press release statement. The company presented preclinical research on a treatment for glioblastoma, a form of brain cancer, developed in collaboration with Taipei Medical University, JY Biomedical Co., Ltd., and HeXun Biosciences Co., Ltd. The research focused on gamma delta T cells, a type of immune cell, administered directly to tumor sites in preclinical models.

The study reported complete tumor elimination by day 26 post-treatment at the highest tested dose, which used an 8:1 ratio of immune cells to cancer cells. The research demonstrated dose-dependent results, with tumor-suppressing effects increasing with dosage. Health screenings and blood panels in the study showed no major safety concerns, according to the company.

"Exhibiting our collaborative work at WCP 2026 was a monumental milestone for our entire team and our partners," said William Wang, Chairman and Chief Executive Officer of SL Science. "We were thrilled to present these findings on a global stage." SL Science develops cellular and gene therapies, with technologies targeting solid tumors including pancreatic and brain cancers.

The company is based in Taiwan and trades on the NASDAQ exchange with a market cap of $700 million. The stock currently trades at $4.33, down 58% year-to-date, reflecting broader investor caution around early-stage biotech firms. The findings presented represent preclinical research and have not yet been tested in human clinical trials.

Investors should note that InvestingPro data shows SLBT trades with high price volatility, with eight additional ProTips available for subscribers analyzing the company’s financial health and market position. In other recent news, SL Science Holding Limited has submitted a request to the U.S. Food and Drug Administration for Orphan Drug Designation. This request pertains to its Vdelta2+ Gamma Delta T Cells therapy, aimed at treating glioblastoma multiforme, a type of brain cancer.

The FDA’s Office of Orphan Products Development has acknowledged the receipt of this request and is currently reviewing additional product files. The designation request is identified under the number DRU-2026-11528. This development is part of SL Science’s ongoing efforts to advance its therapeutic offerings.

The Orphan Drug Designation, if granted, could provide certain benefits and incentives to the company, including market exclusivity and potential tax credits. Investors and stakeholders in SL Science may find this information pertinent as it could impact the company’s future regulatory and market positioning.